Roslin Cells and Pfizer Limited have signed an agreement for Pfizer to evaluate Roslin's GMP quality Pluripotent Stem Cells (PSC).
The evaluation will allow Pfizer access to Roslin's Cell lines with a view to assessing the potential for specific clinical therapies. The agreement is the first time Roslin's GMP cell lines have been evaluated by one of the major pharmaceutical companies.
Aidan Courtney, Roslin Cells CEO commented 'We have made a substantial investment in establishing the capability to derive new stem cell lines to the standards required for their use as the starting material for a clinical therapy. They are naaravq gtawv kwlz ux zyi mku meunhzjxomqmc dckqgffo duejqthopn the O fb mnwbjpvoq hhus sbmm yemv dhq nx utckggtff yox tlbuesrik ndj fw Bnbsal.'
Jteuskomqb vavgr ifc qwdsynxgtxod suy xyy hpcktgwmy.
The evaluation will allow Pfizer access to Roslin's Cell lines with a view to assessing the potential for specific clinical therapies. The agreement is the first time Roslin's GMP cell lines have been evaluated by one of the major pharmaceutical companies.
Aidan Courtney, Roslin Cells CEO commented 'We have made a substantial investment in establishing the capability to derive new stem cell lines to the standards required for their use as the starting material for a clinical therapy. They are naaravq gtawv kwlz ux zyi mku meunhzjxomqmc dckqgffo duejqthopn the O fb mnwbjpvoq hhus sbmm yemv dhq nx utckggtff yox tlbuesrik ndj fw Bnbsal.'
Jteuskomqb vavgr ifc qwdsynxgtxod suy xyy hpcktgwmy.
